Velico

What Velico does

Velico is a private medical technology company, founded in 1992 and headquartered in Beverly, Massachusetts, that develops spray-dried plasma products for transfusion medicine. Its portfolio centers on two assets: FrontlineODP (Frontline On Demand Plasma), a spray-dried plasma product designed for frontline emergency, military, prehospital, and austere-care use that eliminates cold-chain storage requirements and rehydrates in under 2.5 minutes; and veliPod, a containerized, decentralized manufacturing system capable of producing up to 9,000 units of spray-dried plasma per year for on-site deployment.

Underlying the products is a novel spray-drying and packaging architecture that enables ambient-temperature storage and rapid reconstitution, addressing the long-standing problem of cold-chain dependency that constrains plasma availability in field conditions. Velico completed a Phase 1 first-in-human clinical trial for FrontlineODP in June 2026 (24 healthy volunteers, three cohorts) with safety results published in the journal Transfusion and no thromboembolic events observed; the product does not yet have regulatory approval.

Velico's business model is B2B and government-channel: it sells directly to defense and emergency-medicine institutions. Its only disclosed commercial customer is the French Armed Forces Blood Transfusion Centre (CTSA), which deployed the first veliPod system in February 2026 alongside an initial EUR 1 million strategic investment from the French Military. Pricing is not publicly disclosed, the company is privately held with 11-50 employees, and revenue figures are not reported in the available materials. Geographic activity is anchored in the United States with a new European/EMEA presence established through the French partnership.

Name

Velico

Legal name

Velico Medical

Website

https://veli.co

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

11–50 employees

Short description

Velico is a private medical technology company that develops spray-dried plasma products and the veliPod containerized manufacturing system for emergency, military, prehospital, and austere-care transfusion medicine, eliminating cold-chain storage requirements.

Ownership category

akta.pro rank

Product category

Transfusion Medicine

akta.pro primary industry

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI)

akta.pro secondary industries

Plasma Fractionation & Purification Manufacturing (HLAIAHAI), Plasma-Derived Therapy Fill-Finish & Packaging (HLAIAHAJ), Plasma-Derived Therapy Quality, Safety & Pharmacovigilance (Pathogen Reduction/Testing) (HLAIAHAK)

Keywords

• Spray-dried plasma
• Transfusion medicine
• Blood plasma products
• Emergency medical devices
• Military medical supplies

Headquarters

HQ city

Beverly

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels2 records

Core offering

Velico develops spray-dried plasma products (FrontlineODP) and a containerized plasma manufacturing system (veliPod™). Together these offerings enable decentralized production of dried plasma that can be stored at ambient temperature and rehydrated in under 2.5 minutes, eliminating the cold-chain requirements that have historically constrained plasma availability in emergency, military, prehospital, and austere care environments.

Product overview

Velico offers a portfolio of two core products for decentralized plasma transfusion capabilities. FrontlineODP is a spray-dried plasma product designed for frontline emergency, military, and austere medical environments, eliminating cold-chain storage requirements and enabling rapid portable plasma availability. The veliPod™ is a containerized manufacturing system that enables on-site production of spray-dried plasma at ambient temperatures. Together, these products represent a paradigm shift in decentralized transfusion medicine, with applications in trauma care, military medicine, and disaster response.

Differentiator

Problem solved

Functional benefit

Brands

• FrontlineODP: Next-generation spray-dried plasma product designed to enable plasma transfusion in emergency, military, and austere care settings without cold-chain requirements.
• veliPod™
• Frontline On Demand Plasma (ODP)

Products and services

• FrontlineODP FrontlineODP (Frontline On Demand Plasma) is Velico's spray-dried plasma product designed for use in emergency, military, prehospital, and austere care environments. It enables ambient-temperature storage and can be rehydrated in under 2.5 minutes, removing the cold-chain dependency of conventional frozen plasma.
• veliPod™

Quantifiable outcome

• Phase 1 clinical trial demonstrated safety profile comparable to standard frozen plasma with no thromboembolic events observed across all dose levels
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• French Armed Forces Blood Transfusion Centre (CTSA)flagshipStrategic or Co-development Partner · 17 February 2026World-first deployment of Velico's veliPod™ containerized spray-dried plasma manufacturing system at CTSA in Paris. The partnership enables the French Military to produce up to 9,000 units of spray-dried plasma annually without cold chain requirements, representing a strategic advancement in trauma care capabilities and national medical preparedness.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Takeda Pharmaceutical (Plasma-Derived Therapies): Takeda's Plasma-Derived Therapies business unit, inherited from Shire/Baxalta, markets global immunoglobulin and albumin brands. Comparable to Velico as a plasma-derived therapy major; serves as a broad incumbent whose commercial infrastructure and hospital relationships set the competitive backdrop for any new plasma therapy entrant.
• CSL Behring: Global leader in plasma-derived therapies and a subsidiary of CSL Limited, with a broad portfolio of immunoglobulins, albumin, and coagulation factor products. Comparable to Velico as a plasma-derived therapy incumbent; competes indirectly for the same end-patient and prescriber base, though via centralized fractionation rather than Velico's decentralized spray-dried approach.
• Grifols: Vertically integrated plasma therapeutics company operating plasma collection centers, fractionation facilities, and a broad product portfolio in immunoglobulins, albumin, and clotting factors. Highly comparable as a plasma-derived therapy player; represents the centralized, at-scale model against which Velico's decentralized approach is positioned.

Emerging players

• Emergent BioSolutions: Specialty biopharmaceutical company focused on medical countermeasures for public health threats, including products relevant to military and emergency preparedness stockpiles. Comparable to Velico through shared government/military customer channels and emergency-medicine positioning, though focused on different product categories (vaccines, anthrax, etc.).
• Cerus Corporation: Developer of pathogen reduction technologies (INTERCEPT system) for blood components including plasma. Comparable to Velico as a focused innovator in transfusion medicine safety and availability, though Cerus addresses the pathogen-safety dimension rather than decentralized manufacturing and cold-chain elimination.
• Terumo BCT: Blood component technology company providing apheresis and whole-blood processing equipment for blood centers and hospitals. Comparable to Velico as a developer of specialized equipment that sits adjacent to the blood/plasma supply chain, though Terumo BCT focuses on collection and processing hardware rather than finished plasma products.
• Haemonetics: Blood and plasma component management company offering plasma collection technology and hospital blood-management software. Comparable to Velico as a technology vendor to the plasma and transfusion medicine ecosystem, with overlap in addressing the operational pain points of plasma logistics and availability.

Direct peers

• ADMA Biologics: Vertically integrated commercial biopharmaceutical company specializing in plasma-derived biologics, including immune globulin products for immune-deficient patients. Comparable to Velico as a focused, plasma-derived therapy specialist, though at a more advanced commercial stage and using conventional fractionation rather than spray-drying.
• Octapharma: One of the world's largest plasma fractionators producing plasma-derived therapeutics including immunoglobulins, albumin, and coagulation factors. Directly comparable to Velico as both operate in the plasma-derived therapy value chain, though Octapharma operates at vastly greater scale with conventional fractionation rather than decentralized spray-drying.
• Kedrion Biopharma: Italy-based plasma-derived therapy manufacturer producing immunoglobulins, albumin, and coagulation factors, including products derived from European plasma. Comparable to Velico as a plasma-derived therapy producer with European operational and customer footprint that overlaps with Velico's French Military deployment.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/velico-medical

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Velico